Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 12.12.
Forward PE Ratio (12.12) = Close Price ($73.60) / Consensus Forward EPS ($6.25)
FORWARD PE RATIO
12.12
SECTOR MEDIAN · HEALTHCARE
20.01
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
-39.43%
vs the sector median at left
Zoetis Inc.
Market Cap
$30.86B
Forward PE Ratio
12.12
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Zoetis Inc. (ZTS) | $30.86B | 12.12 |
| Biogen Inc. (BIIB)vs › | $31.40B | 17.68 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $30.16B | 13.98 |
| Waters Corporation (WAT)vs › | $30.13B | 28.09 |
| DexCom, Inc. (DXCM)vs › | $31.90B | 32.95 |
| Centene Corp. (CNC)vs › | $31.90B | 13.96 |
| ResMed Inc. (RMD)vs › | $32.06B | 20.53 |
| Medline Inc. (MDLN)vs › | $29.33B | 24.51 |
| Alcon Inc. (ALC)vs › | $33.71B | 19.80 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.80B | 39.61 |
Trailing P/E
12.5
reported TTM EPS
Forward P/E
12.1
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $6.25 implies +3.0% EPS growth vs the reported trailing $6.07.
At today's $73.60 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $6.25 | $6.23 – $6.30 | 9 | 11.8x |
| 2027-12-31 | $6.46 | $6.10 – $6.89 | 10 | 11.4x |
| 2028-12-31 | $7.01 | $5.88 – $8.18 | 6 | 10.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute